Sigma-Aldrich Announces Service Provider for WGA Technology
News May 31, 2006
This follows a recent licensing agreement with Rubicon Genomics, allowing Sigma to offer GenomePlex Whole Genome Amplification kits to service providers.
"We are pleased to be working with MOgene on service opportunities for GenomePlex WGA," said Keith Jolliff, Director of Strategic Marketing at Sigma- Aldrich.
"Their expertise in reproducible genetic processing and experimental design will enable further enhancement of our GenomePlex product line and allow both companies to expand their customer base."
"We offer the highest quality microarray service to customers eager to make use of Agilent's highly sensitive 60-mer oligonucleotide format," said Shaukat Rangwala, VP of MOgene's Research operations.
"The partnership with Sigma-Aldrich for Whole Genome Amplification shows their confidence in our capabilities and allows MOgene to further serve our customers in the area of CGH, where samples are often limited."
In 2004, Sigma announced an exclusive licensing agreement with Rubicon to further develop and commercialize the GenomePlex WGA technology.
The latest addition to the GenomePlex family of products is the Single Cell WGA Kit, which is designed to support whole genome amplification from a single cell resulting in a million-fold amplification of genomic DNA.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.